| 摘要 |
<p>A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a soluble receptor capable of binding to its ligand and thus affecting the ligand's function. The soluble receptor is preferably the soluble form of TNFα receptor. Such compositions are for use in the treatment of disorders in which neutralization of the deleterious effects of TNFα is required.</p> |
